Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Alnylam Pharmaceuticals, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Alnylam Pharmaceuticals, Inc. (ALNY) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alnylam Pharmaceuticals, Inc. (“Alnylam” or “the Company”) (NASDAQ: ALNY). Investors who purchased Alnylam securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Alnylam has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On July 30, 2026, Alnylam announced second-quarter 2026 financial results. Among other things, the Company reported it has “lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy.” As a result, Alnylam lowered its total projected TTR net product revenues by approximately $200 million. Following this news, Alnylam’s stock price dropped as much as $81.25 per share, or 28.35%, during intraday trading on July 30, 2026.
What Should Alnylam Pharmaceuticals, Inc. (ALNY) Investors Do?
If you are aware of any facts relating to this investigation or purchased Alnylam securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
How Is Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Stock Trading Today?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”